Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M104942200 on September 26, 2001

J. Biol. Chem., Vol. 276, Issue 48, 44464-44471, November 30, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/48/44464    most recent
M104942200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhao, D.
Right arrow Articles by Pothoulakis, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, D.
Right arrow Articles by Pothoulakis, C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Signal Transduction Pathways Mediating Neurotensin-stimulated Interleukin-8 Expression in Human Colonocytes*

Dezheng Zhao, Andrew C. KeatesDagger, Sabina Kuhnt-Moore, Mary P. Moyer§, Ciaran P. Kelly, and Charalabos Pothoulakis

From the Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215 and § INCELL Corporation, San Antonio, Texas 78249

Received for publication, May 30, 2001, and in revised form, August 14, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Neurotensin (NT), a neuropeptide released in the gastrointestinal tract in response to several stimuli, is involved in the pathophysiology of colonic inflammation. However, the molecular mechanism(s) mediating this proinflammatory response remains unclear. We found that NCM460, non-transformed human colonocytes, express a functional high affinity NT receptor that mediates NT-induced Erk activation. By using NCM460 cells stably transfected with NTR1, we show that NTR1 activation leads to interleukin (IL)-8 secretion that is mediated via both NF-kappa B- and Erk-dependent pathways. In addition, NT-stimulated NF-kappa B activation is dependent on intracellular calcium release. NT-stimulated Erk activity requires Ras activation because overexpression of the dominant negative Ras mutant Ras-17N almost completely inhibits the Erk activation. Furthermore, NT directly stimulates Ras-GTP formation as shown by a Ras-GTP pull-down assay. By using reporter gene constructs containing targeted substitutions in the IL-8 promoter, we show that the NF-kappa B, AP-1, and to a lesser degree the C/EBP sites in the IL-8 promoter region are required for IL-8 gene expression induced by NT. In summary, our results demonstrate that NT stimulates calcium-dependent NF-kappa B and Ras-dependent Erk pathways that mediate the release of IL-8 from non-transformed human colonocytes. We speculate that these NT-related proinflammatory pathways are important in the pathophysiology of colonic inflammation.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Neurotensin (NT),1 a 13-amino acid neuropeptide originally isolated by Carraway and Leeman (1), is highly expressed in the gastrointestinal tract (2). In the ileal mucosa NT is synthesized and secreted by specific endocrine cells (3), in response to diverse stimuli (4). NT increases small bowel, colonic, and gastric motility and stimulates ileal, pancreatic, and biliary secretion (4, 5) as well as Cl- secretion from human colonic mucosa (6), indicating that this peptide may contribute to the pathophysiology of human diarrhea. NT also stimulates growth of the intestinal mucosa under physiological and pathological conditions and causes proliferation of intestinal epithelial cells in vivo and in vitro (7-11). Two G-protein-coupled receptors (GPCRs) have been described for NT, a high affinity (NTR1) and a low affinity (NTR2) receptor (12). Administration of the specific NTR1 antagonist SR 48692 to rats inhibits colonic mucin and prostaglandin E2 secretion in response to immobilization stress (13), suggesting the importance of NTR1 in stress-mediated colonic responses. Our recent studies (14) demonstrate that NT is a proinflammatory peptide in the colon because blockage of the NT-NTR1 interaction with SR 48692 inhibited colonic secretion and inflammation mediated by Clostridium difficile toxin A. We also showed that, compared with normal colonic epithelial cells, there was a dramatic up-regulation of NTR1 during human colonic inflammation (15) as well as in Clostridium difficile toxin A-mediated colitis (14). NT exerts its proinflammatory effects by interacting with several cell types, including mast cells (13, 14, 16, 17), leukocytes (14, 18), endothelial cells (19), and macrophages (20).

The intracellular events stimulated by NT have been studied previously in human colon and pancreatic cell lines that express endogenous NTR1 (21, 22). NT stimulates the formation of inositol 1,4,5-trisphosphate, increases intracellular calcium (23, 24), and activates Erk, a member of the mitogen-activating protein kinase family (25), in colonic adenocarcinoma HT29 cells and in pancreatic MIA PaCa-2 cells (22). NT also stimulates Erk activation in Chinese hamster ovary cells overexpressing NTR1, which is partially inhibited by PTX and completely blocked by the protein kinase C inhibitor GF 109203X (25). Although NT triggers calcium release and Erk activation, their involvement in NT-induced release of proinflammatory cytokines has not been studied. In addition, the signaling pathways stimulated by NT that lead to Erk activation have not been elucidated.

Studies in human intestinal microvascular endothelial cells showed that NT stimulates translocation and DNA binding activity of NF-kappa B (15). NF-kappa B is a transcriptional factor critical for expression of genes involved in inflammation of the gastrointestinal tract (26-28). It consists of homo- and heterodimers of Rel family proteins, typically p65 and p50, sequestered in an inactive form in the cytoplasm by Ikappa B inhibitory proteins. Upon stimulation, Ikappa Bs become phosphorylated, ubiquitinate, and subsequently degraded, resulting in the nuclear translocation of NF-kappa B and the activation of NF-kappa B-responsive genes. NF-kappa B has been shown to be essential for expression of inflammatory genes such as IL-8. IL-8, a potent chemotactic factor for neutrophils, basophils, and T lymphocytes, has been implicated in the pathogenesis of several gastrointestinal inflammatory states (29-33). Three cis-regulatory elements (AP-1, C/EBP-like, and kappa B-like sites) in the IL-8 promoter region are involved in IL-8 gene expression (34, 35). However, the relative importance of the sites in regulating IL-8 gene expression depends on the cell type and the particular stimulus.

In this study, we utilized NCM460, a non-transformed human colonic epithelial cell line, to investigate the molecular mechanisms by which NT exerts its proinflammatory effects. We found that NCM460 cells express a functional NTR1 receptor. Exposure of NCM460 cells transfected with the NTR1 to NT stimulates IL-8 secretion as well as gene transcription in a time- and dose-dependent manner. We also demonstrate that NF-kappa B and Erk activation are required for NT-induced IL-8 gene expression. Our results indicate that NT-stimulated NF-kappa B DNA binding activity is calcium-dependent. More importantly, we show for the first time that NT stimulates Ras-GTP formation and that NT-induced Erk activation is Ras-dependent.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents

NT was purchased from Phoenix Pharmaceuticals (Belmont, CA). [3,11,-tyrosyl-3,5-3H]NT was from PerkinElmer Life Sciences. BAPTA/AM and sulfasalazine were obtained from Calbiochem. Sulfinpyrazone and collagenase were from Sigma, and Fura-2 AM and Pluronic F127 were from Molecular Probes (Eugene, OR). DNA mini-prep kits were from Qiagen (Valencia, CA). NCM460 cells and culture medium M3D were obtained from INCELL Corporation (San Antonio, TX). BCA reagents for measurement of protein concentration were purchased from Pierce.

Creation of a Stably Transfected Human Colonic NCM460 Cell Line Expressing NTR1 (NCM460-NTR1)

Construction and Functionality of a Puromycin-resistant Retroviral Vector-- To create stably transfected cell lines that selectively grow in medium containing puromycin, we constructed a highly efficient puromycin-resistant expression retroviral vector named pCMBP from the vector pCMMP (kindly provided by Dr. Richard C. Mulligan, Children's Hospital, Harvard Medical School) and pBabe-puro (kindly provided by Dr. Steve R. Farmer, Boston University School of Medicine). The retroviral promoter from pCMMP was removed with the restriction enzymes Sbf and PmlI (the fragment named Sbf-PmlI), and then ligated into the pBabe-puro vector which was first digested with BamHI, end-blunted with Klenow, and digested with PstI. To test the functionality of this vector, we also ligated a bacterial beta -galactosidase gene (lacZ) into the pCMBP vector, by a three-fragment ligation. To achieve that, pBabe-puro was first digested with PstI and EcoRI to remove the entire Moloney murine leukemia virus 5'-long terminal repeat and adjacent sequence. A LacZ fragment was isolated from pBluescript-lacZ by first digesting this plasmid with BamHI, end-blunting with Klenow, and then digesting with EcoRI. The digested vector was then ligated with the fragment Sbf-PmlI and the LacZ fragment. The retroviruses expressing beta -galactosidase were prepared following the procedure described below and used to infect NIH3T3 cells to measure the titer of produced viruses.

Cloning of Full-length Human NTR1 cDNA from NCM460 Cells, Construction of NTR1-expressing Retroviral Vectors-- Total cell RNA was isolated from NCM460 cells by the guanidinium isothiocyanate/phenol/chloroform extract procedure as described previously (36). Two micrograms of RNA were reverse-transcribed with Moloney murine leukemia virus-reverse transcriptase (Invitrogen, Grand Island, NY) according to the manufacturer's instruction. Then 2 µl of RT mix was used for PCR amplification of full-length human NTR1 cDNA using Taq DNA polymerase (Qiagen) under the following conditions: 94 °C, 4 min followed by 35 cycles of 94 °C, 1 min; 60 °C, 1 min and 72 °C, 1 min and then 72 °C, 5 min. The primers were designed based on the published sequence of human NTR1 (GenBankTM accession number X70070; Ref. 37). The forward primer containing an EcoRI site was 5'-agtgaattcGGACTCCAGCGCCCACCATGC-3'; and the reverse primer containing a BamHI site was 5'-taaggatccACACGTTCCGGGGCGCACAGC-3'. A 1315-bp fragment was subcloned into pCR2.1 vector using the TA cloning kit (Invitrogen), and the identity of the DNA was confirmed by DNA sequencing. The NTR1 fragment was then removed from pCR2.1 by EcoRI digestion and ligated into the puromycin-expressing retroviral vector pCMBP (pCMBP-NTR1) described above. Retroviruses containing NTR1 were prepared using pCMBP-NTR1 following the procedure described below.

Preparation of Retroviruses and Infection of NCM460 Cells-- 293T cells (kindly provided by Dr. Richard A. Mulligan) were seeded at a density of 4-5 × 106 cells in 100-mm plates containing 10 ml of 10% FBS/Dulbecco's modified Eagle's medium for 24 h, and the medium was replaced with fresh medium 4 h before transfection. The plasmids pMD-gag-pol, pMD-VSVG (both kindly provided by Dr. Richard C. Mulligan), and pCMBP-NTR1 were combined in a ratio of 3:1:4 and used to prepare transfection mixtures using Effectene Transfection Reagent (Qiagen) according to the manufacturer's instructions. Forty eight hours after transfection, the media were collected and filtered through 0.45-µm disc filters, and the supernatants were either used immediately or stored at -80 °C. Infection of NCM460 cells was carried out as follows. Cells were seeded at 4 × 104 cells/cm2 culture surface for 24 h and incubated with medium containing 2 volumes of filtered virus-containing supernatant and 1 volume of fresh growth media for 16-24 h in the presence of 10 µg/ml Polybrene (Sigma). The infected cells were then incubated in media containing 10% FBS and 2 µg/ml puromycin for 6 days. Positively selected cells were pooled (named NCM460-NTR1 cells) and used for this study.

Ligand Binding Assay

NCM460 cells or NCM460-NTR1 cells in 24-well plates were incubated in M3D media containing 10% FBS until they reached ~80% confluence. The cells were then washed once with PBS and incubated with M3D media for 24 h. The cells were incubated with 0.3 ml of fresh M3D media containing increasing concentrations of [3,11,-tyrosyl-3,5-3H]NT (0.05-20 nM). To determine nonspecific binding, 1 µM NT was added to the incubation mixture. After incubation for 3 h at 4 °C, the cells were placed on ice and washed three times with cold PBS. Cells were then lysed in 0.3 ml of 0.3 M NaOH for 30 min at 37 °C, and the radioactivity in the lysate was measured to determine the amount of ligand bound. All determinations were performed in triplicate. The number of receptors was determined from a saturation curve generated by SigmaPlot 3.0 software (Jandel Scientific, San Raphael, CA).

IL-8 Measurements

IL-8 protein levels in colonic epithelial cell-conditioned media were determined by a double-ligand enzyme-linked immunosorbent assay (ELISA) using goat anti-human IL-8 (R & D Systems Inc.) as described previously (30). Results were expressed as mean ± S.E. (ng/ml). At least three independent experiments were performed for each experimental condition, each with triplicate measurements.

Construction of Human IL-8 Promoter-Luciferase Constructs and Luciferase Assay

Construction of a reporter construct containing 1521 bp (nucleotides -1481 to +40) of the promoter region of human IL-8 gene has been described previously (31). IL-8 reporter constructs containing mutations in NF-kappa B, AP-1, or C/EBP sites were created by overlapping PCR-based site-directed mutagenesis. The substitution mutants were based on the sequences described by Wu et al. (35). The mutated NF-kappa B sequence was cgTTAACTTTCCtct; the mutated AP-1 sequence was gaTATCTCAgg; and the mutated C/EBP sequence was tcAGCTACGAGTcg. The sequences were confirmed by DNA sequencing using primers specific for the pGL2-basic luciferase expression vector (GL primers 1 and 2; Promega Corp., Madison, WI). To determine the IL-8 promoter activity in response to NT, cells were seeded in 12-well plates (0.2 × 106 cells/well) overnight and transiently transfected using Effectene Transfection Reagent (Qiagen) with IL-8 promoter-luciferase constructs or a control luciferase construct pRL-TK (Promega) or other DNA constructs as indicated. Transfected cells were serum-starved for 24 h followed by exposure to NT for 4 h. Firefly and Renilla luciferase activities in cell extracts were measured using Dual-Luciferase Reporter Assay System (Promega). The relative luciferase activity was then calculated by normalizing IL-8 promoter-driven firefly luciferase activity to control Renilla luciferase activity. Data from all experiments are presented as the relative luciferase activity (mean ± S.E.) from at least two independent sets of experiments, each with triplicate measurements.

Electrophoretic Mobility Shift Assays (EMSA)

Nuclear extracts were prepared for DNA binding assays as described previously (38). Cells growing in 100-mm plates were washed 2× with ice-cold PBS and then collected into 1 ml of TNE buffer (40 mM Tris (pH 7.4), 1 mM EDTA, 0.15 M NaCl) and centrifuged at 5000 × g for 10 s. The cell pellets were incubated with 800 µl of buffer A (10 mM Hepes (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM phenylmethylsulfonyl fluoride) for 10 min before addition of 46 µl of 10% Nonidet P-40 for an additional 2 min. Nuclei were pelleted by centrifugation at 5000 × g for 10 s, incubated with 120 µl of buffer B (20 mM Hepes (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 0.1 mM phenylmethylsulfonyl fluoride) for 45 min, and centrifuged at 13,000 × g for 10 min. Ten micrograms of nuclear extracts were incubated with 3 µg of poly(dI-dC) (Promega), 2 µl of bandshift buffer (50 mM MgCl2, 340 mM KCl), and 8 µl of delta buffer (0.1 mM EDTA, 40 mM KCl, 25 mM Hepes (pH 7.6), 8% Ficoll 400, 1 mM dithiothreitol) at 4 °C for 15 min. 32P-Labeled double-stranded oligonucleotide probe (100,000 cpm) was then added to the reaction mixture and incubated for 30 min on ice. For supershift assays, the appropriate antibody was added to the nuclear extract and incubated at 4 °C for 30 min before addition of the probe. The anti-NF-kappa B p65 and anti-p50 as well as normal rabbit IgG (control antibody) were from Santa Cruz Biotechnology (Santa Cruz, CA). Binding of specific nuclear protein to the probe was determined by fractionating the nuclear proteins through a nondenaturing 6% polyacrylamide gel at 200 V for 2 h at room temperature in TBE buffer (80 mM Tris borate, 2 mM EDTA (pH 8.0)). The gel was dried at 80 °C for 2 h under vacuum before exposure to x-ray autoradiography film. The NF-kappa B consensus oligonucleotide was purchased from Promega. The double-stranded oligonucleotide was end-labeled by T4 DNA polynucleotide kinase (New England Biolabs, Beverly, MA) and [gamma -32P]ATP (PerkinElmer Life Sciences).

Intracellular Ca2+ Release

Serum-starved cells grown in 100-mm plates were washed twice with PBS and incubated with 4 ml of collagenase solution (0.2 mg/ml collagenase, 0.2 mg/ml soybean trypsin inhibitor, 1 mg/ml bovine serum albumin, 2 mM EDTA in PBS) at 37 °C for 30 min. Cells were detached by gentle scraping and centrifuged at 1000 rpm for 3 min. Cell pellets were resuspended in 2 ml of Ca2+ buffer (5 mM KCl, 140 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 5.6 mM glucose, 0.1% bovine serum albumin, 0.25 mM sulfinpyrazone, and 10 mM Hepes (pH 7.5)) and centrifuged again at the same speed. Cell pellets were resuspended in 2 ml of Ca2+ buffer containing 1 µg/ml Fura-2 and 0.02% pluronic F-127 and incubated at 37 °C for 30 min. Cells were then collected, centrifuged at 1100 rpm for 3 min, and resuspended in 2 ml of Ca2+ buffer. Half of the cell suspension was preincubated with Me2SO vehicle or BAPTA/AM (50 µM) for 5 min before stimulation with NT. Intracellular Ca2+ concentration was measured with the DeltaScan Illumination System plus Felix software (Photon Technology International, Lawrenceville, NJ).

Erk Phosphorylation Assay

Cells were washed twice with ice-cold PBS and then incubated in RIPA buffer containing a protease inhibitor mixture (Roche Molecular Biochemicals) for 10 min. Cell lysates were centrifuged at 1000 × g for 10 min. Equal amounts of cell extracts were separated by SDS-polyacrylamide gel electrophoresis (10%), and proteins were transferred onto nitrocellulose membranes (Bio-Rad) at 100 V for 1 h at 4 °C. Membranes were blocked in 5% nonfat, dried milk in TBST (50 mM Tris (pH 7.5), 0.15 M NaCl, 0.05% Tween 20) and then incubated with phosphospecific antibodies (0.2 µg/ml) to Erk 1/2 (New England Biolabs, Beverly, MA). Horseradish peroxidase-labeled antibodies were detected by SuperSignal Chemiluminescent Substrate (Pierce).

Ras Activation Assay

Ras activity was measured using a Ras Activation Assay Kit (Upstate Biotechnology Inc., Lake Placid, NY) following the manufacturer's instructions. Briefly, quiescent cells were stimulated with NT (10-7 M), washed 2× with ice-cold PBS, and then incubated with 1× Mg2+ lysis/washing buffer containing a protease inhibitor mixture (Roche Molecular Biochemicals) for 10 min at 4 °C. Cell lysates were centrifuged at 1000 × g for 10 min. The supernatants were then pretreated with glutathione-Sepharose-4B beads (Amersham Pharmacia Biotech) for 30 min and then centrifuged at 1000 × g for 10 min. The supernatants were incubated with Raf-1-RBD-conjugated agarose beads for 30 min at 4 °C, and the beads were washed 3× with 1× Mg2+ lysis buffer. The beads were then boiled with 1× SDS sample buffer, and equal volumes of the samples were subjected to Western blot analysis using a monoclonal antibody against Ras. To normalize the amount of GTP-bound Ras to total amount of Ras, equal volumes of cell lysate were also subjected to Western blot analysis using the Ras monoclonal antibody.

Statistical Analyses

Results were expressed as means ± S.E. Data were analyzed using the SIGMA-STATTM professional statistics software program (Jandel Scientific Software, San Rafael, CA). Analyses of variance with protected t test were used for intergroup comparison.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

NT Stimulates IL-8 Secretion and Gene Transcription in NCM460-NTR1 Cells-- Our recent work (14) demonstrated that NTR1 mediates colonic inflammation. To examine whether NTR1 mediates release of the proinflammatory cytokine IL-8, we used the non-transformed human colonic epithelial cell line, NCM460 (39). We first determined whether NCM460 cells express NTR1 mRNA by RT-PCR, and we examined the functionality of this receptor. Our results show that the NCM460 cells express NTR1 as indicated by an expected 1315-bp PCR product that corresponds to the full-length coding region of human NTR1 cDNA (data not shown). Moreover, when quiescent NCM460 cells were exposed to NT (10-10 to 10-6 M) for 10 min, NT induced Erk phosphorylation even at a concentration of 10-10 M (Fig. 1a). Pretreatment with the specific NTR1 antagonist SR 48692 at a concentration of 10 nM completely inhibited NT (10 nM)-induced Erk activation, indicating that NTR1 mediates this response (Fig. 1b). NT (10-6 M, 4-24 h of exposure), however, failed to stimulate IL-8 secretion (data not shown), suggesting that the levels of the receptor may not be high enough to mediate this response. Therefore, we sought to overexpress NTR1 in NCM460 cells to examine whether increased expression of NTR1 results in IL-8 secretion in response to NT. To do that, the NTR1 cDNA fragment generated by RT-PCR from total mRNA derived from NCM460 cells was subcloned into the retroviral vector pCMBP. Retroviruses expressing NTR1 were produced and used to generate stably transfected NCM460 cell lines expressing NTR1 (NCM460-NTR1) as described under "Experimental Procedures." To find out whether NCM460-NTR1 cells express increased number of NT receptors, we performed a ligand binding assay using [3H]NT. The results (data not shown) demonstrated that compared with the parental NCM460 cell that expressed 24,000 NT receptors per cell, NCM460-NTR1 cells had ~360,000 receptors per cell.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   NT stimulates IL-8 secretion and gene transcription in nontransformed human colonocytes overexpressing NTR1. a, NCM460 cells were incubated in M3D media for 24 h to render cells quiescent and then stimulated with NT (10-10 to 10-6 M) for 10 min. Cell lysates were resolved by SDS-polyacrylamide gel electrophoresis and immunoblotted with anti-phospho-Erk1/2 (upper panel) and anti-Erk2 (lower panel); the latter was used as a protein loading control. b, quiescent NCM460 cells were pretreated with NTR1-specific antagonist SR 48692 (1-50 nM) for 10 min and then treated with NT (10 nM) for 10 min. Erk phosphorylation was measured as in a. c, NCM460 cells stably transfected with NTR1 (NCM460-NTR1) were incubated with M3D media for 24 h and then treated with NT (10-7 M) for the indicated time points. The conditioned media were collected and IL-8 was measured by ELISA. Asterisk indicates p < 0.001, 2-h NT-stimulated cells versus non-stimulated cells. d, NCM460 cells or NCM460-NTR1 cells were rendered quiescent and treated for 4 h with NT at the indicated concentrations, and IL-8 was measured in the conditioned media by ELISA. Asterisk indicates p < 0.01, 10-9 M NT-stimulated cells versus non-stimulated cells. Results are expressed as mean ± S.E. (ng/ml). e, NCM460 cells or NCM460-NTR1 cells were transfected with IL-8 promoter construct with an internal control plasmid as described under "Experimental Procedures." Cells were serum-starved and then treated with NT (10-7 M) for 4 h. Cell extracts were prepared to measure IL-8 promoter activity that was expressed as mean ± S.E. (relative luciferase activity, n = 3). Asterisk indicates p < 0.001, 10-7 M NT-stimulated cells versus non-stimulated cells. Results are from a single experiment each with triplicate determinations, representative of three separate experiments.

Exposure of NCM460-NTR1 cells to NT (10-7 m) strongly stimulated IL-8 secretion with a maximal induction 4 h after NT exposure (Fig. 1c). IL-8 secretion induced by NT was dose-dependent at concentrations ranging between 10-10 and 10-6 M, and a significant (1.6-fold, p < 0.01) induction was obtained at 10-9 M (Fig. 1d). However, NT (10-6 M, 4 h of exposure) could not stimulate IL-8 secretion in the parental NCM460 cells (Fig. 1d). We also determined whether NT stimulates IL-8 gene transcription in quiescent NCM460-NTR1 cells transiently transfected with a luciferase reporter construct containing the human IL-8 promoter. The results showed that NT (10-7 M) significantly stimulated IL-8 promoter-driven luciferase activity by 31-fold in NCM46-NTR1 cells but had no effect in the parental NCM460 cells (Fig. 1e, left). Taken together, these results demonstrate that NT stimulates IL-8 secretion as well as IL-8 gene transcription in NCM460-NTR1 cells.

NT-induced IL-8 Expression Requires NF-kappa B Activation-- To confirm the requirement of NF-kappa B activation for NT-induced IL-8 secretion, we examined whether NT stimulated nuclear translocation and DNA binding activity of NF-kappa B in NCM460-NTR1 cells. NT (10-7 M) dramatically increased DNA binding of a nuclear protein complex that contained NF-kappa B p65 and p50 subunits as shown by supershift assays (Fig. 2a). The specificity of the shifted band was confirmed by preincubating the nuclear extract with a control antibody that did not bind NF-kappa B as well as by addition of excess unlabeled (cold) probe into the binding mixture (Fig. 2a).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2.   NT-induced IL-8 expression requires NF-kappa B activation. a, quiescent NCM460-NTR1 cells were treated with NT (10-7 M) for 30 min, and nuclear extracts were prepared for EMSA using a 32P-labeled NF-kappa B probe as described under "Experimental Procedures." For supershift assays, 2 µg of anti-p65, anti-p50, or normal rabbit IgG were preincubated with nuclear extracts for 30 min on ice before EMSA reactions were performed. b, quiescent cells were pretreated with sulfasalazine (2 mM) for 30 min and then exposed to NT (10-7 M) for 30 min, and NF-kappa B binding activity was examined by EMSA. c, NCM460-NTR1 cells were infected with Ikappa Balpha - or beta -galactosidase (lacZ)- expressing retroviruses and incubated with M3D media for 24 h before treatment with NT (10-7 M) for 4 h for measurement of IL-8 secretion. Asterisk indicates p < 0.01, Ikappa Balpha -expressing cells versus LacZ-expressing cells with NT stimulation. d, NCM460-NTR1 cells were transfected with IL-8 promoter construct with an internal control plasmid and pCMBP-lacZ or pCMBP-Ikappa Balpha . Cells were incubated with M3D media for 24 h and then treated with NT (10-7 M) for 4 h. Cell extracts were prepared to measure IL-8 promoter activity which was expressed as mean ± S.E. (relative luciferase activity, n = 3). Asterisk indicates p < 0.01, Ikappa Balpha -expressing cells versus LacZ-expressing cells with NT stimulation. e, cells were transiently transfected with wild-type or NF-kappa B mutant promoter constructs together with a control luciferase construct. The transfected cells were incubated with media for 24 h and then exposed to NT (10-7 M) for 4 h. Cell extracts were prepared to determine luciferase activity as described under "Experimental Procedures." The results were representative of three separate experiments.

We next determined whether inhibition of NF-kappa B activation blocks NT-induced IL-8 secretion. Pretreatment of NCM460-NTR1 cells with the NF-kappa B inhibitor sulfasalazine significantly inhibited NT-induced NF-kappa B DNA binding activity (Fig. 2b) and IL-8 secretion (data not shown). To confirm the role of NF-kappa B in NT-induced IL-8 expression, we overexpressed Ikappa Balpha , an endogenous NF-kappa B inhibitor. Our data show that NT-induced IL-8 secretion was reduced by 65% in cells overexpressing human Ikappa Balpha , as compared with the control (Fig. 2c). To examine whether overexpression of Ikappa Balpha inhibits NT-induced IL-8 gene transcription, NCM460-NTR1 cells were transiently transfected with the IL-8 luciferase reporter construct together with an Ikappa Balpha plasmid or control vector. Our data clearly indicate that cotransfection with the Ikappa Balpha plasmid significantly reduced NT-induced IL-8 promoter-driven gene transcription (Fig. 2d). To confirm the NF-kappa B requirement for NT-induced IL-8 transcription, we used an IL-8 promoter construct that contained targeted mutations in the NF-kappa B-binding site. The results showed that the NF-kappa B mutant construct did not respond to NT treatment, whereas the wild-type IL-8 promoter construct was strongly activated by NT (Fig. 2e). Thus, NF-kappa B activation is a major requirement for NT-induced IL-8 gene transcription and IL-8 protein release.

Calcium Dependence of NT-induced NF-kappa B Activation and IL-8 Secretion-- NT (10-7 M) stimulated intracellular calcium release in NCM460-NTR1 cells within a few seconds, which returned to control values after ~3 min (Fig. 3a). Moreover, pretreatment of the cells with BAPTA/AM completely inhibited NT-induced Ca2+ release, even below the basal levels (Fig. 3a), and abolished NT-induced IL-8 secretion (Fig. 3b). To find out whether the effect of BAPTA/AM was mediated through NF-kappa B, quiescent NCM460-NTR1 cells were preincubated with BAPTA/AM and then treated with NT (10-7 M), and NF-kappa B DNA binding activity was measured by EMSA. Our results showed that pretreatment with BAPTA/AM significantly attenuated NT-stimulated NF-kappa B DNA binding activity, indicating that the effect of intracellular calcium on NT-induced IL-8 secretion involves NF-kappa B activation (Fig. 3c). We also found that preincubation of NCM460-NTR1 with 20 µM W7, a Ca2+-calmodulin antagonist, or 10 µM of cyclosporin A, an inhibitor of the calcium-dependent phosphatase calcineurin, inhibited NT-induced IL-8 secretion by 61.3 and 60.7%, respectively (p < 0.05, n = 3) (data not shown). These results suggest that the Ca2+-dependent NF-kappa B activation in response to NT might be mediated through Ca2+-activated kinase(s) and phosphatase(s).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Calcium mobilization is essential for NT-induced NF-kappa B activation and IL-8 secretion. a, quiescent NCM460-NTR1 cells were collected from 100-mm plates to determine intracellular calcium release as described under "Experimental Procedures." The cell suspensions were pretreated with Me2SO or BAPTA/AM (50 µM) for 5 min before stimulation with NT. b, cells were pretreated with BAPTA/AM (B/A) (25, 50 µM) for 30 min, treated with NT (10-7 M) for 4 h, and IL-8 release measured in the conditioned media. c, cells were pretreated with BAPTA/AM (50 µM) for 30 min and treated with NT (10-7 M) for 30 min. Nuclear extracts were then prepared, and NF-kappa B DNA binding activity was determined by EMSA. Results are representative of three separate experiments.

Erk Activation Is Required for NT-induced IL-8 Expression-- We next determined whether an Erk-dependent pathway mediates NT-induced IL-8 expression. Quiescent cells were pretreated with PD98059, a specific MAP kinase/Erk kinase inhibitor, and treated with NT (10-7 M) for 4 h to measure IL-8 release and IL-8 promoter-dependent transcription. PD98059 significantly inhibited both NT-induced IL-8 release (Fig. 4a) and IL-8 promoter activity (Fig. 4b), suggesting that Erk activation is involved in NT-induced IL-8 expression.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 4.   Erk activation is required for NT-induced IL-8 expression. a, quiescent NCM460-NTR1 cells were pretreated with PD98059 (50 µM) for 30 min and treated with NT (10-7 M) for 4 h. Conditioned media were then collected for measurement of IL-8 by ELISA. Asterisk indicates p < 0.01, PD98059-treated cells with NT stimulation versus control cells with NT stimulation. b, cells were transfected with wild-type IL-8 promoter construct and serum-starved as described under "Experimental Procedures." Cells were then pretreated with PD98059 (50 µM) for 30 min and treated with NT (10-7 M) for 4 h. Cell extracts were made to determine luciferase activity. Asterisk indicates p < 0.001, PD98059-treated cells with NT stimulation versus control cells with NT stimulation. The results were representative of three individual experiments, each with triplicate determinations.

NT Stimulates Ras-GTP Formation-- To examine whether Ras is upstream of NT-induced Erk activation, we first examined whether NT directly activates Ras using a Ras-GTP pull-down assay (40). Quiescent MCM460-NTR1 cells were treated with NT (10-7 M) for various times or EGF for 3 min, and the levels of Ras-GTP in the cell extracts were then measured. We found that NT increased Ras-GTP loading from 3 to 5 min after NT exposure. As expected, EGF (100 ng/ml) strongly stimulated Ras-GTP loading (Fig. 5). These data demonstrate for the first time that binding of NT to NTR1 activates Ras.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 5.   NT stimulates Ras-GTP formation. Quiescent cells were treated with NT (10-7 M) for the indicated times. Cell extracts were then prepared, and equal amounts of protein were used to measure the levels of GTP-bound Ras as described under "Experimental Procedures." Equal amount of cell extracts were also subjected to Western blot analysis using the monoclonal antibody directed against Ras to confirm equal protein loading.

NT-induced Erk Activation Is Ras-dependent-- It is known that GPCR-stimulated Erk activation can be Ras-dependent or Ras-independent (41, 42). However, whether Ras is involved in the NT signaling pathway is not known. To explore this possibility, we used a dominant negative Ras mutant Ras-17N to block downstream events of Ras activation. NCM460-NTR1 cells were infected with the Ras-17N-expressing retroviruses and then rendered quiescent. Cells were then exposed to either NT (10-7 M) or PMA (2 µM), a phorbol ester that activates Erk in a Ras-independent manner (43), or EGF (100 ng/ml), which is known to activate Erk in a Ras-dependent manner. We found that the dominant negative Ras mutant blocked Erk activation induced by NT and, as expected, by EGF (Fig. 6) but had no effect on PMA-induced Erk activation (Fig. 6). Thus, NT-induced activation of the Erk pathway is Ras-dependent.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 6.   NT-induced Erk activation is Ras-dependent. NCM460-NTR1 cells were infected with LacZ (Z)- or Ras-17N (R)-expressing retroviruses and then incubated with M3D for 24 h before stimulated with NT (10-7 M), PMA (2 µM), or EGF (100 ng/ml) for 10 min. Cell lysates were used to determine the Erk1/2 phosphorylation as well as the total Erk2 (a protein loading control) as described in Fig. 1a.

Because increased intracellular calcium is involved in angiotensin (II)-induced Erk activation in vascular smooth muscle cells (44), we tested the possibility that calcium participates in NT-induced Erk activation. After pretreatment with BAPTAM/AM (50 µM) for 30 min, cells were treated with NT (10-7 M) for 5 min. The data indicated that BAPTA/AM had no effect on NT-induced Erk activation (n = 2 independent experiments, data not shown). We also examined the effect of PTX on NT-induced Erk activation. NCM460-NTR1 cells were pretreated with PTX (100 ng/ml) overnight and treated with lysophosphatidic acid (50 µM) or NT (10-7 M) for 10 min. The results (not shown) indicated that PTX almost completely inhibited lysophosphatidic acid-induced Erk activation but had no effect on NT-induced Erk activation. Taken together, our results demonstrate that NT-stimulated Erk activation is Ras-dependent but does not require increased intracellular calcium and PTX-sensitive Gi/o proteins.

Dominant Negative Ras Inhibits NT-induced IL-8 Expression-- To determine whether Ras activation is required for NT-induced IL-8 secretion and IL-8 gene transcription, NCM460-NTR1 cells were infected with Ras-17N-expressing retroviral vectors and then exposed to NT (10-7 M) for 4 h. Expression of the dominant negative Ras significantly inhibited NT-induced IL-8 protein release (Fig. 7a). To explore whether the Ras-17N mutant also inhibited NT-induced IL-8 transcription, cells were transfected with the Ras-17N construct along with IL-8 promoter-luciferase construct and then exposed to NT (10-7 M) for 4 h. As shown in Fig. 7b, overexpression of Ras-17N significantly inhibited NT-stimulated IL-8 promoter activity.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of dominant negative Ras on NT-induced IL-8 expression. a, NCM460-NTR1 cells were infected with Ras-17N- or LacZ-expressing retroviruses and then incubated with M3D media for 24 h before exposed to NT (10-7 M) for 4 h. IL-8 was then measured in the conditioned media by ELISA. Asterisk indicates p < 0.01, Ras-17N-expressing cells with NT stimulation versus LacZ-expressing cells with NT stimulation. b, cells were transiently transfected with Ras-17N construct or control LacZ plasmid along with IL-8 promoter-luciferase construct. Cells were incubated with M3D media for 24 h and then incubated with NT (10-7 M) for 4 h, and luciferase activity was measured. Asterisk indicates p < 0.001, Ras-17N-expressing cells with NT stimulation versus LacZ-expressing cells with NT stimulation. The results are representative of the three separate experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have reported previously (14, 15) that NTR1 are up-regulated in colonic inflammation and presented indirect evidence for increased expression of NTR1 receptors on colonic epithelial cells. This study shows that NCM460 human colonic epithelial cells express the high affinity NT receptor that mediates Erk activation in response to NT. Moreover, exposure of NCM460 cells overexpressing NTR1 to NT caused secretion of the potent chemoattractant IL-8 in a time- and dose-dependent manner. NT-induced IL-8 secretion and gene transcription were dependent on NF-kappa B and Erk activation. In addition, NT-mediated NF-kappa B activation was mediated by intracellular calcium release. We also report here for the first time that NT stimulates Ras activity which is required for NT-induced Erk activation and that both calcium and Ras activation are involved in IL-8 release in response to NT.

Our studies demonstrate that the mechanism of NF-kappa B activation and IL-8 secretion in response to NT in colonocytes is calcium-dependent. Interestingly, calcium-dependent NF-kappa B activation is required for IL-8 expression induced by the neuropeptide substance P in human monocytes (45). The mechanisms by which intracellular calcium release leads to activation of NF-kappa B activity following NT exposure have not been elucidated. Exposure of cells to various stimuli such as cytokines triggers a signaling cascade causing phosphorylation and subsequent degradation of Ikappa B proteins leading to the release, activation, and nuclear translocation of NF-kappa B (46). The effect of increased intracellular calcium on Ikappa B phosphorylation may be mediated by a calcium-calmodulin-dependent pathway as W7, a calmodulin-antagonist, can inhibit Ikappa B degradation (47, 48). In addition, the calcium-dependent protein phosphatase calcineurin may synergize with protein kinase C to activate NF-kappa B by a yet unknown mechanism (47, 49, 50). Our observation that W7 or cyclosporin A partially inhibited NT-induce IL-8 secretion suggests that multiple calcium-dependent pathways may be involved in NF-kappa B activation following NT exposure.

Our results indicate that Erk is required for NT-induced IL-8 promoter activity and IL-8 production, supporting a proinflammatory role for MAP kinases in the NTR1 signaling pathway. Previous results also support a major role for MAP kinases in IL-8 secretion. For example, the inhibitor of p38 MAP kinase, SB203580, and the inhibitor of MAP kinase/Erk kinase, PD98059, significantly inhibited IL-8 release induced by C. difficile toxin A in human monocytes (31) as well as by Helicobacter pylori in gastric epithelial cells (33). Although both MAP kinase and NF-kappa B are required for IL-8 gene expression in response to many stimuli, involvement of MAP kinase pathways in NF-kappa B activation appears to be dependent on the particular stimulus. For instance, Erk and p38 MAP kinase activation following H. pylori exposure did not appear to be associated with NF-kappa B stimulation (33). Similarly, in synovial fibroblasts the p38 MAP kinase inhibitor SB203580 reduced IL-8 induction in response to IL-1beta without affecting nuclear translocation of NF-kappa B (51). However a RSK-MAPK-pp90rsk pathway was shown to be required for Pseudomonas aeruginosa-induced NF-kappa B-dependent gene expression and mucin overproduction in epithelial cells (52). In addition, our results demonstrate that Erk is also involved in NT-induced NF-kappa B-dependent gene expression as PD98059 inhibited NF-kappa B-driven luciferase activity. In addition to the NF-kappa B site, the IL-8 promoter contains binding sites for the transcription factors, AP-1 and C/EBP. Our experiments also indicate that the AP-1- and C/EBP-binding sites were involved in NT-induced IL-8 promoter activity (data not shown). Along these lines, a MAP kinase-dependent pathway is known to activate the transcriptional activity of AP-1 as well as expression of c-jun and c-fos, the two subunits of the transcriptional factor AP-1 (53, 54). Taken together, NT-mediated IL-8 expression in human colonocytes involves both NF-kappa B and MAP kinase-dependent pathways.

Although NT-stimulated Erk activation in Chinese hamster ovary cells expressing NTR1 was partially inhibited by PTX and completely blocked by the protein kinase C inhibitor GF 109203X (25), the pathway that leads to Erk activation is not clear. Our results demonstrate that a dominant negative Ras mutant Ras-17N completely inhibited NT-induced Erk phosphorylation and significantly reduced NT-induced IL-8 expression. Moreover, NT stimulated Ras-GTP loading. To our knowledge, this is the first report to show that NT activates Ras and that NT-induced Erk activation is Ras-dependent. The exact mechanism whereby NT stimulates Ras-dependent Erk activation in a Gi/o protein and calcium-independent manner remains to be elucidated. It is known that Ras-dependent Erk activation by GPCR can be mediated through multiple mechanisms. One is PTX-sensitive Gi/o-dependent pathway in which the beta gamma subunits released from activated Gi/o proteins recruit the protein-tyrosine kinase Src, leading to subsequent activation of the Ras-Erk pathway (55-57). Another pathway leading to Ras-dependent Erk activation is via the calcium-dependent tyrosine kinase Pyk2, which is triggered by PTX-insensitive Gq and phospholipase Cbeta (58). However, the inability of PTX or BAPTA/AM to affect NT-induced Erk activation in our study indicates that these two pathways are unlikely to mediate NT-induced Ras-dependent Erk activation. In addition, transactivation of the EGF receptor has also been shown to mediate Erk activation induced by many GPCRs such as the receptors for lysophosphatidic acid, thrombin (59), and neuropeptide substance P (60). The possibility that the transactivation of the EGF receptor is involved in NT-induced Erk activation remains to be elucidated.

In summary, our findings that NT induces expression of pro-inflammatory cytokine IL-8 via Ca2+-dependent NF-kappa B and Ras-dependent Erk activation further our understanding of the molecular mechanism by which this neuropeptide mediates its pro-inflammatory effect in the gastrointestinal tract.

    ACKNOWLEDGEMENTS

We thank Dr. Richard C. Mulligan, Dr. Steve R. Farmer, and Dr. Debabrata Mukhopadhyay for kindly providing some of plasmids used in this study. We would like to thank Sanofi Recherche (Toulouse, France) for kindly providing the NTRI antagonist SR-48692.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants DK 33506 (to C. P.) and DK54920 (to C. P. K.) and by the Crohn's and Colitis Foundation of America.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Recipient of Career Development award from the Crohn's and Colitis Foundation of America.

To whom correspondence should be addressed: Beth Israel Deaconess Medical Center, Division of Gastroenterology, Dana 501, 330 Brookline Ave., Boston, MA 02215. Tel.: 617-667-1259; Fax: 617-667-5071; E-mail: cpothoul@caregroup.harvard.edu.

Published, JBC Papers in Press, September 26, 2001, DOI 10.1074/jbc.M104942200

    ABBREVIATIONS

The abbreviations used are: NT, neurotensin; GPCR, guanine nucleotide-binding protein-coupled receptor; Erk, extracellular signal-regulated protein kinase; BAPTA/AM, 1,2-bis(o-aminophenooxy)ethane-N,N,N',N'-tetraacetic acid, acetoxymethyl ester; PMA, phorbol 12-myristate acetate; PTX, pertussis toxin; IL, interleukin; NTR, neurotensin receptor; EGF, epidermal growth factor; RT-PCR, reverse transcriptase-polymerase chain reaction; bp, base pair; FBS, fetal bovine serum; PBS, phosphate-buffered saline; ELISA, enzyme-linked immunosorbent assay; EMSA, electrophoretic mobility shift assay(s); MAP, mitogen-activated protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Carraway, R., and Leeman, S. E. (1973) J. Biol. Chem. 248, 6854-6861
2. Carraway, R., and Leeman, S. E. (1976) J. Biol. Chem. 251, 7045-7052
3. Polak, J. M., Sullivan, S. N., Bloom, S. R., Buchan, A. M., Facer, P., Brown, M. R., and Pearse, A. G. (1977) Nature 270, 183-184
4. Walsh, J. H. (1987) in Physiology of the Gastrointestinal Tract (Johnson, L. R., ed), 2nd Ed. , pp. 181-253, Raven Press, Ltd., New York
5. Thor, K., and Rosell, S. (1986) Gastroenterology 90, 27-31
6. Riegler, M., Castagliuolo, I., Wang, C., Wlk, M., Sogukoglu, T., Wenzl, E., Matthews, J. B., and Pothoulakis, C. (2000) Gastroenterology 119, 348-357
7. Wood, J. G., Hoang, H. D., Bussjaeger, L. J., and Solomon, T. E. (1988) Am. J. Physiol. 255, G813-G817
8. Wood, J. G., Hoang, H. D., Bussjaeger, L. J., and Solomon, T. E. (1988) Pancreas 3, 332-339
9. Yoshinaga, K., Evers, B. M., Izukura, M., Parekh, D., Uchida, T., Townsend, C. M., and Thompson, J. C. (1992) Surg. Oncol. 1, 127-134
10. Maoret, J. J., Anini, Y., Rouyer-Fessard, C., Gully, D., and Laburthe, M. (1999) Int. J. Cancer 80, 448-454
11. Evers, B. M., Izukura, M., Chung, D. H., Parekh, D., Yoshinaga, K., Greeley, G. H., Uchida, T., Townsend, C. M., and Thompson, J. C. (1992) Gastroenterology 103, 86-91
12. Vincent, J. P., Mazella, J., and Kitabgi, P. (1999) Trends Pharmacol. Sci. 20, 302-309
13. Castagliuolo, I., Leeman, S. E., Bartolak-Suki, E., Nikulasson, S., Qiu, B., Carraway, R. E., and Pothoulakis, C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 12611-12615
14. Castagliuolo, I., Wang, C. C., Valenick, L., Pasha, A., Nikulasson, S., Carraway, R. E., and Pothoulakis, C. (1999) J. Clin. Invest. 103, 843-849
15. Castagliuolo, I., Valenick, L., Pasha, A., Sturniolo, G. C., D'Incá, R. D., Fiocchi, C., and Pothoulakis, C. (1999) Gastroenterology 116, 799
16. Pothoulakis, C., Castagliuolo, I., and Leeman, S. E. (1998) Ann. N.Y. Acad. Sci. 840, 635-648
17. Miller, L. A., Cochrane, D. E., Carraway, R. E., and Feldberg, R. S. (1995) Br. J. Pharmacol. 114, 1466-1470
18. Goldman, R., Bar-Shavit, Z., and Romeo, D. (1983) FEBS Lett. 159, 63-67
19. Schaeffer, P., Laplace, M. C., Savi, P., Pflieger, A. M., Gully, D., and Herbert, J. M. (1995) J. Biol. Chem. 270, 3409-3413
20. Lemaire, I. (1988) J. Immunol. 140, 2983-2988
21. Ehlers, R. A., Bonnor, R. M., Wang, X., Hellmich, M. R., and Evers, B. M. (1998) Surgery 124, 239-246
22. Ehlers, R. A., Zhang, Y., Hellmich, M. R., and Evers, B. M. (2000) Biochem. Biophys. Res. Commun. 269, 704-708
23. Amar, S., Kitabgi, P., and Vincent, J. P. (1986) FEBS Lett. 201, 31-36
24. Bozou, J. C., Rochet, N., Magnaldo, I., Vincent, J. P., and Kitabgi, P. (1989) Biochem. J. 264, 871-878
25. Poinot-Chazel, C., Portier, M., Bouaboula, M., Vita, N., Pecceu, F., Gully, D., Monroe, J. G., Maffrand, J. P., Le Fur, G., and Casellas, P. (1996) Biochem. J. 320, 145-151
26. Schmid, R. M., Adler, G., and Liptay, S. (1998) Gut 43, 587-588
27. Ellis, R. D., Goodlad, J. R., Limb, G. A., Powell, J. J., Thompson, R. P., and Punchard, N. A. (1998) Inflamm. Res. 47, 440-445
28. Ardite, E., Panes, J., Miranda, M., Salas, A., Elizalde, J. I., Sans, M., Arce, Y., Bordas, J. M., Fernandez-Checa, J. C., and Pique, J. M. (1998) Br. J. Pharmacol. 124, 431-433
29. Papadakis, K. A., and Targan, S. R. (2000) Annu. Rev. Med. 51, 289-298
30. Linevsky, J. K., Pothoulakis, C., Keates, S., Warny, M., Keates, A. C., Lamont, J. T., and Kelly, C. P. (1997) Am. J. Physiol. 273, G1333-G1340
31. Warny, M., Keates, A. C., Keates, S., Castagliuolo, I., Zacks, J. K., Aboudola, S., Qamar, A., Pothoulakis, C., LaMont, J. T., and Kelly, C. P. (2000) J. Clin. Invest. 105, 1147-1156
32. Bliss, C. M., Jr., Golenbock, D. T., Keates, S., Linevsky, J. K., and Kelly, C. P. (1998) Infect. Immun. 66, 5357-5363
33. Keates, S., Keates, A. C., Warny, M., Peek, R. M., Murray, P. G., and Kelly, C. P. (1999) J. Immunol. 163, 5552-5559
34. Okamoto, S., Mukaida, N., Yasumoto, K., Rice, N., Ishikawa, Y., Horiguchi, H., Murakami, S., and Matsushima, K. (1994) J. Biol. Chem. 269, 8582-8589
35. Wu, G. D., Lai, E. J., Huang, N., and Wen, X. (1997) J. Biol. Chem. 272, 2396-2403
36. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159
37. Vita, N., Laurent, P., Lefort, S., Chalon, P., Dumont, X., Kaghad, M., Gully, D., Le Fur, G., Ferrara, P., and Caput, D. (1993) FEBS Lett. 317, 139-142
38. Fried, M., and Crothers, D. M. (1981) Nucleic Acids Res. 9, 6505-6525
39. Moyer, M. P., Manzano, L. A., Merriman, R. L., Stauffer, J. S., and Tanzer, L. R. (1996) In Vitro Cell. Dev. Biol. Anim. 32, 315-317
40. Taylor, S. J., and Shalloway, D. (1996) Curr. Biol. 6, 1621-1627
41. Takeda, H., Matozaki, T., Takada, T., Noguchi, T., Yamao, T., Tsuda, M., Ochi, F., Fukunaga, K., Inagaki, K., and Kasuga, M. (1999) EMBO J. 18, 386-395
42. Blaukat, A., Barac, A., Cross, M. J., Offermanns, S., and Dikic, I. (2000) Mol. Cell. Biol. 20, 6837-6848
43. Ueda, Y., Hirai, S., Osada, S., Suzuki, A., Mizuno, K., and Ohno, S. (1996) J. Biol. Chem. 271, 23512-23519
44. Lucchesi, P. A., Bell, J. M., Willis, L. S., Byron, K. L., Corson, M. A., and Berk, B. C. (1996) Circ. Res. 78, 962-970
45. Lieb, K., Fiebich, B. L., Berger, M., Bauer, J., and Schulze-Osthoff, K. (1997) J. Immunol. 159, 4952-4958
46. Baldwin, A. S. (1996) Annu. Rev. Immunol. 14, 649-683
47. Mattila, P. S., Ullman, K. S., Fiering, S., Emmel, E. A., McCutcheon, M., Crabtree, G. R., and Herzenberg, L. A. (1990) EMBO J. 9, 4425-4433
48. Hughes, K., Antonsson, A., and Grundstrom, T. (1998) FEBS Lett. 441, 132-136
49. Steffan, N. M., Bren, G. D., Frantz, B., Tocci, M. J., O'Neill, E. A., and Paya, C. V. (1995) J. Immunol. 155, 4685-4691
50. Trushin, S. A., Pennington, K. N., Algeciras-Schimnich, A., and Paya, C. V. (1999) J. Biol. Chem. 274, 22923-22931
51. Suzuki, M., Tetsuka, T., Yoshida, S., Watanabe, N., Kobayashi, M., Matsui, N., and Okamoto, T. (2000) FEBS Lett. 465, 23-27
52. Li, J. D., Feng, W., Gallup, M., Kim, J. H., Gum, J., Kim, Y., and Basbaum, C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5718-5723
53. Hsu, T. C., Young, M. R., Cmarik, J., and Colburn, N. H. (2000) Free Radic. Biol. Med. 28, 1338-1348
54. Whitmarsh, A. J., and Davis, R. J. (1996) J. Mol. Med. 74, 589-607
55. Koch, W. J., Hawes, B. E., Allen, L. F., and Lefkowitz, R. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12706-12710
56. Crespo, P., Xu, N., Simonds, W. F., and Gutkind, J. S. (1994) Nature 369, 418-420
57. Luttrell, L. M., Ferguson, S. S., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F., Kawakatsu, H., Owada, K., Luttrell, D. K., Caron, M. G., and Lefkowitz, R. J. (1999) Science 283, 655-661
58. Dikic, I., Tokiwa, G., Lev, S., Courtneidge, S. A., and Schlessinger, J. (1996) Nature 383, 547-550
59. Daub, H., Weiss, F. U., Wallasch, C., and Ullrich, A. (1996) Nature 379, 557-560
60. Castagliuolo, I., Valenick, L., Liu, J., and Pothoulakis, C. (2000) J. Biol. Chem. 275, 26545-26550


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
H.-W. Koon, Y. S. Kim, H. Xu, A. Kumar, D. Zhao, I. Karagiannides, P. R. Dobner, and C. Pothoulakis
Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2,4,6,-trinitrobenzensulphonic acid-induced colitis
PNAS, May 26, 2009; 106(21): 8766 - 8771.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
E Kokkotou, D O Espinoza, D Torres, I Karagiannides, S Kosteletos, T Savidge, M O'Brien, and C Pothoulakis
Melanin-concentrating hormone (MCH) modulates C difficile toxin A-mediated enteritis in mice
Gut, January 1, 2009; 58(1): 34 - 40.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. Kokkotou, A. C. Moss, D. Torres, I. Karagiannides, A. Cheifetz, S. Liu, M. O'Brien, E. Maratos-Flier, and C. Pothoulakis
Melanin-concentrating hormone as a mediator of intestinal inflammation
PNAS, July 29, 2008; 105(30): 10613 - 10618.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
A. C Moss, P. Anton, T. Savidge, P. Newman, A. S Cheifetz, J. Gay, S. Paraschos, M. W. Winter, M. P Moyer, K. Karalis, et al.
Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2{alpha}
Gut, September 1, 2007; 56(9): 1210 - 1217.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
J. Li, K. L. O'Connor, X. Cheng, F. C. Mei, T. Uchida, C. M. Townsend Jr, and B. M. Evers
Cyclic Adenosine 5'-Monophosphate-Stimulated Neurotensin Secretion Is Mediated through Rap1 Downstream of both Epac and Protein Kinase A Signaling Pathways
Mol. Endocrinol., January 1, 2007; 21(1): 159 - 171.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. S. Kim, V. Rajagopal, C. Gonsalves, C. Johnson, and V. K. Kalra
A Novel Role of Hypoxia-Inducible Factor in Cobalt Chloride- and Hypoxia-Mediated Expression of IL-8 Chemokine in Human Endothelial Cells
J. Immunol., November 15, 2006; 177(10): 7211 - 7224.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
X. Wang, Q. Wang, K. L. Ives, and B. M. Evers
Curcumin Inhibits Neurotensin-Mediated Interleukin-8 Production and Migration of HCT116 Human Colon Cancer Cells.
Clin. Cancer Res., September 15, 2006; 12(18): 5346 - 5355.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Souaze, S. Dupouy, V. Viardot-Foucault, E. Bruyneel, S. Attoub, C. Gespach, A. Gompel, and P. Forgez
Expression of Neurotensin and NT1 Receptor in Human Breast Cancer: A Potential Role in Tumor Progression.
Cancer Res., June 15, 2006; 66(12): 6243 - 6249.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
I. Karagiannides, E. Kokkotou, M. Tansky, T. Tchkonia, N. Giorgadze, M. O'Brien, S. E. Leeman, J. L. Kirkland, and C. Pothoulakis
Induction of colitis causes inflammatory responses in fat depots: Evidence for substance P pathways in human mesenteric preadipocytes
PNAS, March 28, 2006; 103(13): 5207 - 5212.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Kim, S. H. Rhee, E. Kokkotou, X. Na, T. Savidge, M. P. Moyer, C. Pothoulakis, and J. T. LaMont
Clostridium difficile Toxin A Regulates Inducible Cyclooxygenase-2 and Prostaglandin E2 Synthesis in Colonocytes via Reactive Oxygen Species and Activation of p38 MAPK
J. Biol. Chem., June 3, 2005; 280(22): 21237 - 21245.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. Zhao, Y. Zhan, H. Zeng, H.-W. Koon, M. P. Moyer, and C. Pothoulakis
Neurotensin Stimulates Interleukin-8 Expression through Modulation of I{kappa}B{alpha} Phosphorylation and p65 Transcriptional Activity: Involvement of Protein Kinase C{alpha}
Mol. Pharmacol., June 1, 2005; 67(6): 2025 - 2031.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Zhao, Y. Zhan, H. W. Koon, H. Zeng, S. Keates, M. P. Moyer, and C. Pothoulakis
Metalloproteinase-dependent Transforming Growth Factor-{alpha} Release Mediates Neurotensin-stimulated MAP Kinase Activation in Human Colonic Epithelial Cells
J. Biol. Chem., October 15, 2004; 279(42): 43547 - 43554.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. H. Rhee, A. C. Keates, M. P. Moyer, and C. Pothoulakis
MEK Is a Key Modulator for TLR5-induced Interleukin-8 and MIP3{alpha} Gene Expression in Non-transformed Human Colonic Epithelial Cells
J. Biol. Chem., June 11, 2004; 279(24): 25179 - 25188.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
T. Weiss, I. Shalit, H. Blau, S. Werber, D. Halperin, A. Levitov, and I. Fabian
Anti-Inflammatory Effects of Moxifloxacin on Activated Human Monocytic Cells: Inhibition of NF-{kappa}B and Mitogen-Activated Protein Kinase Activation and of Synthesis of Proinflammatory Cytokines
Antimicrob. Agents Chemother., June 1, 2004; 48(6): 1974 - 1982.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Toy-Miou-Leong, C. L. Cortes, A. Beaudet, W. Rostene, and P. Forgez
Receptor Trafficking via the Perinuclear Recycling Compartment Accompanied by Cell Division Is Necessary for Permanent Neurotensin Cell Sensitization and Leads to Chronic Mitogen-activated Protein Kinase Activation
J. Biol. Chem., March 26, 2004; 279(13): 12636 - 12646.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Yoshida, A. Kumar, Y. Koyama, H. Peng, A. Arman, J. A. Boch, and P. E. Auron
Interleukin 1 Activates STAT3/Nuclear Factor-{kappa}B Cross-talk via a Unique TRAF6- and p65-dependent Mechanism
J. Biol. Chem., January 16, 2004; 279(3): 1768 - 1776.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
D. Zhao, S. Kuhnt-Moore, H. Zeng, J. S. Wu, M. P. Moyer, and C. Pothoulakis
Neurotensin stimulates IL-8 expression in human colonic epithelial cells through Rho GTPase-mediated NF-kappa B pathways
Am J Physiol Cell Physiol, June 1, 2003; 284(6): C1397 - C1404.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Simeonidis, I. Castagliuolo, A. Pan, J. Liu, C.-C. Wang, A. Mykoniatis, A. Pasha, L. Valenick, S. Sougioultzis, D. Zhao, et al.
Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-kappa B site on its promoter
PNAS, March 4, 2003; 100(5): 2957 - 2962.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
S. Martin, J.-P. Vincent, and J. Mazella
Involvement of the Neurotensin Receptor-3 in the Neurotensin-Induced Migration of Human Microglia
J. Neurosci., February 15, 2003; 23(4): 1198 - 1205.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Zeng, D. Zhao, and D. Mukhopadhyay
KDR Stimulates Endothelial Cell Migration through Heterotrimeric G Protein Gq/11-mediated Activation of a Small GTPase RhoA
J. Biol. Chem., November 22, 2002; 277(48): 46791 - 46798.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
Y. Osawa, M. Nagaki, Y. Banno, D. A. Brenner, T. Asano, Y. Nozawa, H. Moriwaki, and S. Nakashima
Tumor Necrosis Factor Alpha-Induced Interleukin-8 Production via NF-{kappa}B and Phosphatidylinositol 3-Kinase/Akt Pathways Inhibits Cell Apoptosis in Human Hepatocytes
Infect. Immun., November 1, 2002; 70(11): 6294 - 6301.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Z. H. Nemeth, E. A. Deitch, C. Szabo, and G. Hasko
Hyperosmotic Stress Induces Nuclear Factor-{kappa}B Activation and Interleukin-8 Production in Human Intestinal Epithelial Cells
Am. J. Pathol., September 1, 2002; 161(3): 987 - 996.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Graness, C. E. Chwieralski, D. Reinhold, L. Thim, and W. Hoffmann
Protein Kinase C and ERK Activation Are Required for TFF- peptide-stimulated Bronchial Epithelial Cell Migration and Tumor Necrosis Factor-alpha -induced Interleukin-6 (IL-6) and IL-8 Secretion
J. Biol. Chem., May 17, 2002; 277(21): 18440 - 18446.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Zeng, D. Zhao, and D. Mukhopadhyay
Flt-1-mediated Down-regulation of Endothelial Cell Proliferation through Pertussis Toxin-sensitive G Proteins, beta gamma Subunits, Small GTPase CDC42, and Partly by Rac-1
J. Biol. Chem., February 1, 2002; 277(6): 4003 - 4009.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/48/44464    most recent
M104942200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhao, D.
Right arrow Articles by Pothoulakis, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, D.
Right arrow Articles by Pothoulakis, C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement